Medtronic Announces Key Activities at American Heart Association Scientific Sessions 2008

Consistent with its long-standing commitment to clinical excellence in advanced cardiac care, Medtronic, Inc. (NYSE: MDT) today announced key activities during Scientific Sessions 2008, at the annual congress of the American Heart Association, being held Nov. 8-12, 2008 at the Morial Convention Center in New Orleans. Of note, evidence further demonstrating the clinical benefit of painless anti-tachycardia pacing (ATP) will be presented. Additionally, the first U.S. clinical trial data on the Melody® transcatheter pulmonic heart valve will be presented, representing the first time U.S. clinical trial data has been presented on the use of a transcatheter valve in a population with congenital heart disease. Both sessions will be held Monday, Nov. 10:

• Differences in Effects of Electrical Therapy for Ventricular Arrhythmias on Mortality in ICD patients, from 9:15-9:30 a.m. in Room 243-245, presented by Michael O. Sweeney, M.D., Brigham and Women’s Hospital, Boston.
• Implantation of the Medtronic Melody Transcatheter Pulmonary Valve in Patients with Dysfunctional Right Ventricular Outflow (RVOT) Conduits: Procedural and 6-Month Results from U.S. Feasibility Trial, from 2-2:15 p.m. in Room 220-222, presented by Doff B. McElhinney, M.D., Children’s Hospital, Boston.

Clinical data from studies sponsored or supported by Medtronic will be featured in more than 30 presentations during Scientific Sessions 2008. Additionally, congress attendees are encouraged to visit Medtronic’s main booth no. 401, where the following presentations will be held:

Sunday, Nov. 9

• Controversies in the Identification, Assessment and Treatment of Heart Failure: Findings from the IMPROVE HF Study, from 11:30 a.m.-noon featuring Gregg Fonarow, M.D., UCLA Medical Center
• Product Innovation and Quality: How to Balance Risk Versus Benefit, from 12:45-1:15 p.m. featuring Larry Rosenthal, M.D., UMass Memorial Medical Center

Monday, Nov. 10

• Cardiac Resynchronization Therapy is a Class I Indication: Why Are Only 1/3 Being Treated?, from 11:30 a.m.-noon featuring William T. Abraham, M.D., The Ohio State University
• New Evidence that Reducing Shocks May Prolong Survival in ICD Patients, from 12:15-12:45 p.m. featuring Michael O. Sweeney, M.D., Brigham and Women’s Hospital
• Managing HF Patients Based on OptiVol® and CareAlerts™, from 1-1:30 p.m. featuring Carsten Stoepel, M.D., Lukas Hospital Neuss

Attendees will have the opportunity to learn more about the improved Medtronic CareLink® Network, Vision 3D™ portfolio of products, CardioSight® Service, and many of the leading products Medtronic has developed for physicians to deliver better care to their patients. Innovations from Medtronic CardioVascular’s international product portfolio on display will include:

• Driver® and Micro-Driver® bare-metal stents
• Endeavor® and Endeavor Resolute™ drug-eluting stents
• Sprinter® Legend™ angioplasty balloon catheter
• Export® thrombus aspiration catheter
• Interceptor® coronary filter system
• Talent™ Stent Grafts for aortic aneurysm repair
• Melody® transcatheter pulmonic heart valve

Visitors also are encouraged to stop by the Medtronic Mobile Therapy and Procedure Training Center at booth no. 119 to practice lead placement and simulate coronary interventional procedures inside the firm’s Virtual Cath Lab® and explore real human and animal hearts in various disease stages, as provided by the Medtronic-supported Visible Heart® Lab.

About Medtronic

Medtronic, Inc. (www.medtronic.com), headquartered in Minneapolis, is the global leader in medical technology – alleviating pain, restoring health, and extending life for millions of people around the world.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic’s Annual Report on Form 10-K for the year ended April 25, 2008. Actual results may differ materially from anticipated results.